Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 21

1.

Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.

Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, Maki RG, Ou SH, Dezube BJ, Jänne PA, Costa DB, Varella-Garcia M, Kim WH, Lynch TJ, Fidias P, Stubbs H, Engelman JA, Sequist LV, Tan W, Gandhi L, Mino-Kenudson M, Wei GC, Shreeve SM, Ratain MJ, Settleman J, Christensen JG, Haber DA, Wilner K, Salgia R, Shapiro GI, Clark JW, Iafrate AJ.

N Engl J Med. 2010 Oct 28;363(18):1693-703. doi: 10.1056/NEJMoa1006448. Erratum in: N Engl J Med. 2011 Feb 10;364(6):588.

PMID:
20979469
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Phase II study of dasatinib in patients with advanced non-small-cell lung cancer.

Johnson FM, Bekele BN, Feng L, Wistuba I, Tang XM, Tran HT, Erasmus JJ, Hwang LL, Takebe N, Blumenschein GR, Lippman SM, Stewart DJ.

J Clin Oncol. 2010 Oct 20;28(30):4609-15. doi: 10.1200/JCO.2010.30.5474. Epub 2010 Sep 20.

PMID:
20855820
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR.

Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I, Fujita Y, Okinaga S, Hirano H, Yoshimori K, Harada T, Ogura T, Ando M, Miyazawa H, Tanaka T, Saijo Y, Hagiwara K, Morita S, Nukiwa T; North-East Japan Study Group.

N Engl J Med. 2010 Jun 24;362(25):2380-8. doi: 10.1056/NEJMoa0909530.

PMID:
20573926
[PubMed - indexed for MEDLINE]
Free Article
4.

Phase I/II study of the Src inhibitor dasatinib in combination with erlotinib in advanced non-small-cell lung cancer.

Haura EB, Tanvetyanon T, Chiappori A, Williams C, Simon G, Antonia S, Gray J, Litschauer S, Tetteh L, Neuger A, Song L, Rawal B, Schell MJ, Bepler G.

J Clin Oncol. 2010 Mar 10;28(8):1387-94. doi: 10.1200/JCO.2009.25.4029. Epub 2010 Feb 8.

PMID:
20142592
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

Effects of Src kinase inhibition induced by dasatinib in non-small cell lung cancer cell lines treated with cisplatin.

Ceppi P, Papotti M, Monica V, Lo Iacono M, Saviozzi S, Pautasso M, Novello S, Mussino S, Bracco E, Volante M, Scagliotti GV.

Mol Cancer Ther. 2009 Nov;8(11):3066-74. doi: 10.1158/1535-7163.MCT-09-0151. Epub 2009 Oct 27.

PMID:
19861409
[PubMed - indexed for MEDLINE]
Free Article
6.

Src kinases as therapeutic targets for cancer.

Kim LC, Song L, Haura EB.

Nat Rev Clin Oncol. 2009 Oct;6(10):587-95. doi: 10.1038/nrclinonc.2009.129. Review.

PMID:
19787002
[PubMed - indexed for MEDLINE]
7.

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.

Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, Sunpaweravong P, Han B, Margono B, Ichinose Y, Nishiwaki Y, Ohe Y, Yang JJ, Chewaskulyong B, Jiang H, Duffield EL, Watkins CL, Armour AA, Fukuoka M.

N Engl J Med. 2009 Sep 3;361(10):947-57. doi: 10.1056/NEJMoa0810699. Epub 2009 Aug 19.

PMID:
19692680
[PubMed - indexed for MEDLINE]
Free Article
8.

Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK.

Shaw AT, Yeap BY, Mino-Kenudson M, Digumarthy SR, Costa DB, Heist RS, Solomon B, Stubbs H, Admane S, McDermott U, Settleman J, Kobayashi S, Mark EJ, Rodig SJ, Chirieac LR, Kwak EL, Lynch TJ, Iafrate AJ.

J Clin Oncol. 2009 Sep 10;27(26):4247-53. doi: 10.1200/JCO.2009.22.6993. Epub 2009 Aug 10.

PMID:
19667264
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

The role of Src in solid tumors.

Wheeler DL, Iida M, Dunn EF.

Oncologist. 2009 Jul;14(7):667-78. doi: 10.1634/theoncologist.2009-0009. Epub 2009 Jul 6. Review.

PMID:
19581523
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

SRC promotes survival and invasion of lung cancers with epidermal growth factor receptor abnormalities and is a potential candidate for molecular-targeted therapy.

Leung EL, Tam IY, Tin VP, Chua DT, Sihoe AD, Cheng LC, Ho JC, Chung LP, Wong MP.

Mol Cancer Res. 2009 Jun;7(6):923-32. doi: 10.1158/1541-7786.MCR-09-0003. Epub 2009 Jun 2.

PMID:
19491201
[PubMed - indexed for MEDLINE]
Free Article
11.

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).

Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J.

Eur J Cancer. 2009 Jan;45(2):228-47. doi: 10.1016/j.ejca.2008.10.026.

PMID:
19097774
[PubMed - indexed for MEDLINE]
12.

Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial.

Gatzemeier U, Pluzanska A, Szczesna A, Kaukel E, Roubec J, De Rosa F, Milanowski J, Karnicka-Mlodkowski H, Pesek M, Serwatowski P, Ramlau R, Janaskova T, Vansteenkiste J, Strausz J, Manikhas GM, Von Pawel J.

J Clin Oncol. 2007 Apr 20;25(12):1545-52.

PMID:
17442998
[PubMed - indexed for MEDLINE]
Free Article
13.

SRC-family kinases are activated in non-small cell lung cancer and promote the survival of epidermal growth factor receptor-dependent cell lines.

Zhang J, Kalyankrishna S, Wislez M, Thilaganathan N, Saigal B, Wei W, Ma L, Wistuba II, Johnson FM, Kurie JM.

Am J Pathol. 2007 Jan;170(1):366-76.

PMID:
17200208
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer.

Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R, Johnson DH.

N Engl J Med. 2006 Dec 14;355(24):2542-50. Erratum in: N Engl J Med. 2007 Jan 18;356(3):318.

PMID:
17167137
[PubMed - indexed for MEDLINE]
Free Article
15.

Dasatinib (BMS-354825) selectively induces apoptosis in lung cancer cells dependent on epidermal growth factor receptor signaling for survival.

Song L, Morris M, Bagui T, Lee FY, Jove R, Haura EB.

Cancer Res. 2006 Jun 1;66(11):5542-8.

PMID:
16740687
[PubMed - indexed for MEDLINE]
Free Article
16.

Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer).

Thatcher N, Chang A, Parikh P, Rodrigues Pereira J, Ciuleanu T, von Pawel J, Thongprasert S, Tan EH, Pemberton K, Archer V, Carroll K.

Lancet. 2005 Oct 29-Nov 4;366(9496):1527-37.

PMID:
16257339
[PubMed - indexed for MEDLINE]
17.

TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer.

Herbst RS, Prager D, Hermann R, Fehrenbacher L, Johnson BE, Sandler A, Kris MG, Tran HT, Klein P, Li X, Ramies D, Johnson DH, Miller VA; TRIBUTE Investigator Group.

J Clin Oncol. 2005 Sep 1;23(25):5892-9. Epub 2005 Jul 25.

PMID:
16043829
[PubMed - indexed for MEDLINE]
Free Article
18.

Erlotinib in lung cancer - molecular and clinical predictors of outcome.

Tsao MS, Sakurada A, Cutz JC, Zhu CQ, Kamel-Reid S, Squire J, Lorimer I, Zhang T, Liu N, Daneshmand M, Marrano P, da Cunha Santos G, Lagarde A, Richardson F, Seymour L, Whitehead M, Ding K, Pater J, Shepherd FA.

N Engl J Med. 2005 Jul 14;353(2):133-44. Erratum in: N Engl J Med. 2006 Oct 19;355(16):1746.

PMID:
16014883
[PubMed - indexed for MEDLINE]
Free Article
19.

Determinants of tumor response and survival with erlotinib in patients with non--small-cell lung cancer.

Pérez-Soler R, Chachoua A, Hammond LA, Rowinsky EK, Huberman M, Karp D, Rigas J, Clark GM, Santabárbara P, Bonomi P.

J Clin Oncol. 2004 Aug 15;22(16):3238-47.

PMID:
15310767
[PubMed - indexed for MEDLINE]
Free Article
20.

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.

Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J, Haber DA.

N Engl J Med. 2004 May 20;350(21):2129-39. Epub 2004 Apr 29.

PMID:
15118073
[PubMed - indexed for MEDLINE]
Free Article
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk